Noelia Jara-Rico

Noelia Jara-Rico

Auto-generated profile, based on publicly available information

Noelia Jara-Rico

Department of Dermatology, Dr. Balmis General University Hospital, 03010 Alicante, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2024 in Children
Verified
Journal Article
Open access
PDF file
IBIsabel Betlloch-Mas
Isabel Betlloch-Mas
EVElena Boluda Verdú
Elena Boluda Verdú
NJNoelia Jara-Rico
Noelia Jara-Rico
Verónica Sánchez-GarcíaVerónica Sánchez-García
Verónica Sánchez-García
LGLaura Berbegal-De Gracia
Laura Berbegal-De Gracia
ECEusebi Chiner
Eusebi Chiner
We conducted a two-year retrospective evaluation of infants aged under two years with a confirmed, clinical, or suspected diagnosis of scabies in a healthcare center in Alicante (Spain) to determine possible factors associated with diagnostic delay and poor treatment response. We collected epidemiological, clinical, diagnostic, and treatment variables. After describing our findings as mean values and percentages, we compared categorical variables using the Student’s t-test and the Mann–Whitney U test, and we compared continuous variables with the Chi2 test and Pearson’s correlation coefficient. We included 51 infants (19 boys and 32 girls) with a mean age of 15 months. The main source of contagion was the family; half of the infants lived with four or more people. According to the International Consensus Criteria for the Diagnosis of Scabies, confirmed scabies was diagnosed in 45% of cases and clinical scabies in 47%, and 45% of cases had a diagnostic delay. Lesions mainly affected the hands, feet, and trunk, with papules in 92% of cases and burrows in 55%. The predominant symptoms were pruritus (94%) and irritability (69%). Regarding treatment, 98% of the infants received topical permethrin and 35% received oral ivermectin. Treatment failed in 76% of infants. Living in large family units was associated with a higher risk of contagion and therapeutic failure. Diagnostic delay was associated with previous misdiagnosis.

26 September 2023 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MSMarina Senent-Valero
Marina Senent-Valero
AMAlicia Matijasevich
Alicia Matijasevich
NJNoelia Jara-Rico
Noelia Jara-Rico
Francisca SiveraFrancisca Sivera
Francisca Sivera
JPJosé C Pascual
José C Pascual
Despite there being published studies on the survival of oral retinoids and biological drugs in people with hidradenitis suppurativa (HS), there is little scientific evidence on the use of metformin in this setting. We conducted a single-centre, retrospective cohort study in Spain, between January 2015 and December 2021 to determine the drug survival of metformin at 12 months in people with HS in a real-world setting. We concluded that drug survival of metformin is relatively long: half the patients were still on the drug after 1 year of treatment and one in five patients were still on the drug after 2 years.